Intaglob 16.5% Injection
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Intaglob 16.5% Injection contains normal human immunoglobulin (IgG). Its labelling describes it as replacement therapy that supplies antibodies the body cannot make on its own, to strengthen the immune response and lower the risk of infection in people with a weakened immune system. It is described as effective in preventing infection in bone marrow transplant patients over 20 years of age during the first 100 days after transplant, and as raising platelet counts in certain blood disorders.
Product Information
The following description reflects information associated with normal human immunoglobulin (IgG) and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described as replacement therapy for people with impaired antibody production, to lower the risk of infection
- Described for the prevention of infection in bone marrow transplant patients over 20 years of age during the first 100 days after transplant
- Described as raising platelet counts in patients with certain blood disorders
- Described as suitable for both children and adults
Described Dosage & Administration
- Administered only by a doctor or nurse as an injection — not self-administered
- The dose and interval are set by the doctor according to the condition being treated
- Health monitoring may be arranged by the doctor to check for side effects
Described Side Effects
Commonly described side effects include:
- Flushing (a sense of warmth in the face, ears, neck, and trunk)
- Injection-site reactions (pain, swelling, redness, soreness, bruising)
- Induration (hardening of the tissue at the injection site)
- Itching
- Rash
These are described as commonly temporary. Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- The doctor should be told about any problems with blood clotting
- The doctor should be told about any recent or planned vaccination, as immunoglobulin can affect the response to some vaccines
- The doctor should be consulted about suitability during pregnancy or breastfeeding
- Any persistent or severe side effect should be reviewed by a clinician
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains normal human immunoglobulin (IgG) and is used as replacement therapy for people with impaired antibody production, including the prevention of infection in bone marrow transplant patients over 20 years of age in the first 100 days after transplant, and to raise platelet counts in certain blood disorders. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling states it is administered by a doctor or nurse as an injection, at the dose and interval set by the doctor. Health monitoring may be arranged to check for side effects.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.